Europe Top News and Analysis Switzerland

More

  • Nestle, the world's largest food company, will raise prices, cull unprofitable products and speed up production rationalization to prepare for a lasting rise in commodity and energy prices.

  • UBS is preparing a new growth initiative in the United States that may include acquisitions as it seeks to bolster its investment banking and wealth management business, the Swiss group's chairman said on Sunday.

  • Food prices around the world are set for a "significant and long-lasting" period of inflation because of a variety of factors, including demand from China and India, Nestle's chairman Peter Brabeck said in an interview with the Financial Times today.

  • The state of Massachusetts accused UBS of providing hedge fund traders with favors intended to win brokerage business for the investment bank, according to a report.

  • Shares of Ventana Medical Systems soared on Tuesday, on news that Roche Holding made a $3 billion tender offer for the company.

  • Shares of Julius Baer Holding fell Friday after UBS said late Thursday that it would sell its 20.7% stake in the Swiss private bank.

  • Larry Smith, chief investment officer at Third Wave Global Investors, told CNBC’s “Street Signs” that interest rates in Switzerland are significantly lower than in the United Kingdom, creating an opportunity for investors.

  • Swiss private bank EFG International said on Wednesday it would buy Toronto-based Bull Wealth Management, further pursuing its strategy of growing rapidly through acquisitions.

  • Adecco said it has signed an agreement to fully acquire Germany's Tuja Group for a total consideration of around 800 million euros ($1.07 billion) , with the acquisition seen earnings enhancing as of 2007. Adecco said the transaction, which is still subject to regulatory approval, significantly strengthens its position in the German temporary staffing market, one of the fastest growing of its kind in the industry worldwide.

  • The Swiss National Bank raised interest rates by 25 basis points for the seventh quarter running on Thursday, and said more increases were likely if the economy remained strong.

  • A Swiss judge acquitted all 19 former executives of failed airline Swissair of criminal wrongdoing on Thursday, ending Switzerland's biggest-ever economic crime trial.

  • The Swiss unemployment rate fell to 2.7% in May from 2.9% in April, Switzerland's State Secretariat for Economic Affairs (Seco) said.

  • Swiss Re is set to buy nearly 4 billion pounds ($7.90 billion) worth of U.K. life insurance liabilities from Swiss insurer Zurich Financial, the Wall Street Journal said on Friday. Both Zurich Financial and Swiss Re declined to comment on the story, which said terms of the deal were not known.

  • Switzerland's first quarter gross domestic product grew a real (or inflation-adjusted) 0.8% from the fourth quarter of last year and increased a 2.4% year-on-year, the Swiss state secretariat for economic affairs (SECO) said.

  • UBS said Friday it plans to sell its 20.7% stake in private bank Julius Baer Holding to raise capital for its share repurchase program.

  • Swatch Group, the world's biggest watchmaker, is betting on a luxury goods boom in the United States and a recovering Japan as its sales continue to show double-digit growth, its chief executive said on Wednesday.

  • Swisscom reported a below consensus first-quarter EBIT of 619 million sfr, down from 686 million sfr the year before, hit by lower margins and higher costs, due to the market launch of its Bluewin TV offering and other new businesses.

  • The Swiss unemployment rate fell to 2.9% in April, from 3.0% in March, Switzerland's State Secretariat for Economic Affairs (Seco) said.

  • Converium Holdings has issued an appeal to Scor shareholders urging them to vote against the French insurer's capital increase at its AGM on Apr 26, thereby blocking the takeover bid for Converium.

  • Fast-selling cancer drugs boosted first-quarter sales at Roche Holding by 16% to 11.4 billion Swiss francs ($9.41 billion), the Swiss drugmaker said, raising its outlook for the full year.